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ystatin C (Cys-C) is a 122-amino acid, 13-kDa protein
hat is a member of a family of competitive inhibitors of
ysteine proteases (1). Cys-C is produced by all human
ucleated cells, and the human Cys-C gene is of the
ousekeeping type, which indicates a stable production rate
f Cys-C by most nucleated cell types. Cys-C has several
roperties that make it a good candidate marker of glomer-
lar filtration rate (GFR), including a constant production
ate, free filtration at the glomerulus, complete reabsorption,
nd catabolism by the proximal tubules with no reabsorp-
ion into the bloodstream, and no renal tubular secretion
2). Serum Cys-C is a good marker of renal function and
orrelates better to direct measures of GFR more precisely
See page 1930
han creatinine, because its serum concentrations are inde-
endent of muscle mass and do not seem to be affected by
ge or sex (3,4). The development of automated and rapid
article-enhanced immunoturbidimetric and immunoneph-
lometric methods have allowed large-scale use of serum
ys-C as a clinically useful GFR marker. However, several
actors have been reported to influence the production of
ys-C; large doses of glucocorticoids have been described to
ncrease the production of Cys-C, whereas low and medium
oses of glucocorticoids do not seem to alter the production
f Cys-C (5). Thyroid dysfunction also has a major impact
n Cys-C level. In contrast to creatinine concentrations,
ys-C levels are lower in the hypothyroid and higher in the
yperthyroid state as compared with the euthyroid state
1,6,7).
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s associated with an increase in cardiovascular risk and
ortality (8,9). Therefore, as Cys-C is a more accurate
urrogate marker of renal function compared with plasma
reatinine, it is not surprising that several cohort- and
opulation-based studies have demonstrated that Cys-C is
n important prognostic indicator of cardiovascular and
verall mortality. Data from the Cardiovascular Health
tudy, a cohort study of elderly persons living in the
ommunity, demonstrated that Cys-C is a stronger predic-
or of the risk of death and cardiovascular events in elderly
ersons than is creatinine (10,11). The Heart and Soul
tudy reported an association of Cys-C with mortality,
ardiovascular events, and incident heart failure among
ersons with coronary heart disease (12). Cys-C has also
een proven to be a good predictor of outcome in suspected
r confirmed non–ST-segment elevation acute coronary
yndrome and acute heart failure (13). Finally, Maahs et al.
14), reported that serum Cys-C predicts progression of
ubclinical coronary atherosclerosis in individuals with type
diabetes.
In this issue of the Journal, Wu et al. (15) reported that
ys-C is prognostic of long-term mortality in the subjects
ith relatively normal renal function determined by
reatinine-based estimated glomerular filtration rate
eGFR). The authors measured Cys-C in 2,990 subjects
ver 40 years old with normal eGFR who participated in the
hird National Health and Nutrition Examination Survey
NHANES III). Normal eGFR was defined by 60 ml/
in/1.73 m2, as determined by the Modification of Diet in
enal Disease (MDRD) equation. When the first and last
eciles of Cys-C were compared, the relative risks of
ll-cause, cardiovascular, cancer, and noncardiovascular
ortalities were all increased statistically. Hazard ratios all
oderated to lower values when the comparisons were
xpanded to include the upper and lower thirds. Similar
ssociations were still present when Cys-C was modeled on
continuous scale, suggesting a linear relationship between
ys-C and mortality outcomes. The current study confirms
hat indeed, Cys-C has added prognostic value to conven-
ional estimates of GFR based on serum creatinine mea-
urement. This is consistent with the previous findings of
hlipak et al. (16), who reported, using the Cardiovascular
ealth Study, that among elderly persons without chronic
idney disease, Cys-C is a prognostic biomarker of risk for
eath and cardiovascular disease. Importantly, the current
tudy also included younger patients up to 40 years of age.
Does Cys-C have prognostic value independent of renal
unction or is it a better marker for preclinical or mild renal
ysfunction as compared to creatinine-based estimate of
enal function?
An important limitation of the study by Wu et al. (15) is
he lack of direct measurement of GFR. Hence, we cannot
etermine the extent to which Cys-C concentration reflects
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Cystatin C: Beyond Renal Function? November 30, 2010:1937–8f GFR using plasma creatinine either by the MDRD or the
ockcroft-Gault (C-G) formula has its limitations (17). In
he current study, the authors defined “normal” renal func-
ion as eGFR by MDRD equation 60 ml/min/1.73 m2.
owever, the subjects in the 90th and greater percentile of
ys-C have impaired renal function as compared with
ubjects in the 10th or lower percentile of Cys-C levels,
vident by higher percentage of subjects with microalbu-
inuria, higher blood urea nitrogen, and lower eGFR.
urthermore, in the multivariate analysis, eGFR is associ-
ted with significant risk of all-cause and cardiovascular
ortality. Hence, the data from the current study do not
nswer the question of whether indeed, Cys-C is an
ndicator of increased risk of long-term mortality indepen-
ent of true renal function, or whether it is a better marker
or mild renal dysfunction as compared to creatinine-based
stimation of GFR. Pucci et al. (18) completed an elegant
tudy comparing Cys-C with the creatinine-based C-G
ormula and the MDRD study equation for the assessment
f early decreased renal function in 288 diabetic patients to
he goal standard of determination of GFR by iohexol
learance. The authors found that Cys-C was better corre-
ated with GFR than were creatinine-based C-G and
DRD, only in patients with normal renal function (GFR
60 ml/min/1.73 m2) but not in those with decreased
FR. The authors concluded that serum Cys-C is more
seful as compared with conventional estimates based on
erum creatinine measurement for detecting very early
eduction of renal function. Shlipak et al. (16) also had the
imilar conclusion that Cys-C seems to identify a “preclin-
cal” state of kidney dysfunction that is not detected with
erum creatinine or eGFR. Although it is academically and
cientifically interesting to determine whether Cys-C has
rognostic value independent of true renal function, the
ndings of the study by Wu et al. (15) and previous studies
ave established that Cys-C has added prognostic value in
ubjects with normal creatinine-based eGFR.
uture Research Directions
t would be very clinically relevant to determine whether
erial measurements of Cys-C has added prognostic value
nd whether therapeutic interventions will result in the
ecrease of Cys-C with improved clinical outcome. If
ndeed that is true, we should then test whether Cys-C may
e used as a biomarker to guide therapy for patients.
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